Altimmune Inc (NASDAQ: ALT) kicked off on Friday, up 2.23% from the previous trading day, before settling in for the closing price of $5.38. Over the past 52 weeks, ALT has traded in a range of $2.90-$7.73.
Healthcare Sector giant saw their annual sales surged by 3.48% over the last five years. While this was happening, its average annual earnings per share was recorded 27.05%. With a float of $103.59 million, this company’s outstanding shares have now reached $104.34 million.
Altimmune Inc (ALT) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Altimmune Inc is 0.72%, while institutional ownership is 40.01%. The most recent insider transaction that took place on Jan 08 ’26, was worth 20,410. In this transaction Director of this company bought 5,000 shares at a rate of $4.08, taking the stock ownership to the 13,498 shares. Before that another transaction happened on Dec 29 ’25, when Company’s Director bought 527 for $3.80, making the entire transaction worth $2,003. This insider now owns 527 shares in total.
Altimmune Inc (ALT) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.33 earnings per share (EPS), higher than consensus estimate (set at -0.34) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 27.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.04% during the next five years compared to 3.48% growth over the previous five years of trading.
Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators
Take a look at Altimmune Inc’s (ALT) current performance indicators. Last quarter, stock had a quick ratio of 17.18. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 28694.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.07, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.23 in one year’s time.
